Directory

>

Andrew Kolodziej

avatar

Andrew Kolodziej

Executive Director, Regulatory Toxicology | Corbus Pharmaceuticals

Cambridge, Massachusetts, United States

View contact details (it's free)

Andrew Kolodziej

Summary

Andrew Kolodziej is a seasoned professional in regulatory toxicology and translational pharmacology, currently serving as the Executive Director at Corbus Pharmaceuticals. With a robust background in drug development, he has specialized expertise in early-stage discovery through Phase 2 development, focusing on toxicology and regulatory submissions. His experience spans various disease areas, including cardiovascular diseases and oncology, with a particular interest in protein homeostasis related to conditions like Cystic Fibrosis and Alzheimer's. Andrew has a proven track record in leading teams and managing complex projects, having held senior roles in multiple organizations, including Keros Therapeutics and Flatley Discovery Lab. He is a co-inventor of innovative MRI contrast imaging agents and has secured significant funding for research initiatives. Andrew's academic foundation includes a Ph.D. in Chemistry from MIT and a B.S. from the University of Chicago, underscoring his strong scientific acumen. His passion for advancing therapeutics is evident in his ongoing contributions to the field, particularly in the development of biomarkers and novel drug compounds.

General

Specialist

Technical Background

Leadership Experience

Long-Term Tenure

Professional interests

Emerging Technologies

Leadership Development

Innovation

Organisational experience

Corporate Experience

Andrew Kolodziej

Work Experience

company logo

Executive Director, Regulatory Toxicology at

Corbus Pharmaceuticals

July 2020 - Present

company logo

Sr. Director Toxicology at

Keros Therapeutics

July 2019 - October 2019

company logo

Vice President, Nonclinical Safety and CMC at

Flatley Discovery Lab

November 2015 - July 2019

company logo

Vice President, Research at

Flatley Discovery Lab

November 2011 - November 2015

company logo

Consulting Director of Research at

COLLAGEN MEDICAL, LLC

January 2011 - November 2011

company logo

Director, Drug Discovery and Development at

Eutropics

July 2009 - December 2010

company logo

Project Leader at

EPIX Pharmaceuticals

January 2007 - January 2009

company logo

Scientist at

EPIX Pharmaceuticals

January 1996 - January 2008

company logo

Post Doctoral Fellow at

University Of California Berkeley

January 1991 - January 1996

company logo

Graduate Student at

Mit

January 1985 - January 1991

company logo

Student at

University Of Chicago

January 1982 - January 1985

Logos provided by Logo.dev

Andrew Kolodziej

Education

Massachusetts Institute of Technology, Ph.D.

January 1989 - January 1991

University of Chicago, B.S.

January 1981 - January 1985

University High school

Frequently Asked Questions about Andrew Kolodziej

What is Andrew Kolodziej email address?

Andrew Kolodziej's primary email address is **********@corbuspharma.com. To view the full verified email and additional contact details, sign up for free with Muraena.

What company does Andrew Kolodziej work for?

Andrew Kolodziej is a Executive Director, Regulatory Toxicology at Corbus Pharmaceuticals, a company specializing in Biological products, except diagnostic.

Where Andrew Kolodziej graduated from?

Andrew Kolodziej holds a degree in Chemistry from Massachusetts Institute of Technology.

How can I directly contact Andrew Kolodziej?

To contact Andrew Kolodziej directly, you can use the email address **********@corbuspharma.com. Complete contact information is available upon registration with Muraena.

Who is Andrew Kolodziej?

Andrew Kolodziej is a seasoned professional in regulatory toxicology and translational pharmacology, currently serving as the Executive Director at Corbus Pharmaceuticals. With a robust background in drug development, he has specialized expertise in early-stage discovery through Phase 2 development, focusing on toxicology and regulatory submissions. His experience spans various disease areas, including cardiovascular diseases and oncology, with a particular interest in protein homeostasis related to conditions like Cystic Fibrosis and Alzheimer's. Andrew has a proven track record in leading teams and managing complex projects, having held senior roles in multiple organizations, including Keros Therapeutics and Flatley Discovery Lab. He is a co-inventor of innovative MRI contrast imaging agents and has secured significant funding for research initiatives. Andrew's academic foundation includes a Ph.D. in Chemistry from MIT and a B.S. from the University of Chicago, underscoring his strong scientific acumen. His passion for advancing therapeutics is evident in his ongoing contributions to the field, particularly in the development of biomarkers and novel drug compounds.

Andrew`s contact details

mail

**********@corbuspharma.com

Colleagues

avatar
Pete Salzmann

Board Member

avatar
Sean Moran

Chief Financial Officer

avatar
Yuval Cohen

Chief Executive Officer

avatar
Meghan Houghton

Vice President of Finance

View Contact details (it's free)
Request Profile Removal